Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE. The company has submitted the results to the Central Drugs ...

In 11.1.5 there will be eight total masks available which is an increase of three from Battle for Azeroth. In any run, you can equip as many Faceless Masks as you want to (up to eight total).

In the dose-escalation and dose-expansion portions of the phase 1 trial evaluating CT-95, experts will assess its safety, tolerability, pharmacokinetics, and antitumor activity, including overall ...

Brant's banner is in the second half of WuWa 2.1 (Image via Kuro Games) New banners for the second half of Wuthering Waves 2.1 begin on March 6, 2025, at 10 am (server time), and will last until ...

There are two forms of immersion cooling – single phase and dual phase. In single phase cooling, the liquid stays liquid throughout the cycle (i.e. it keeps its phase constant).

"We are encouraged by the positive findings from the Phase 1 trial, particularly the successful completion of the final DSMB review, which reinforces PP-007’s safety profile,” says Dr. Italo ...

The Primary 1 registration results have been released with six primary schools left with no spots. The results came out as scheduled on Tuesday (13 July). The Ministry of Education (MOE) releases the ...

Key Takeaways SOL-1 Phase 3 trial for OTX-TKI has randomized over 300 patients, closing randomization by December 2024. OTX-TKI aims to be a durable wet AMD therapy, potentially dosed every six to ...

A power-conversion system for converting three-phase power into single-phase power is proposed in this paper. The proposed three-phase to single-phase (3φ/1φ) power-conversion system comprises a power ...

Completion of Phase 1 culminates a major effort by the STEP Demo team, which began in 2013 to establish a working sCO2 power cycle with backing from the U.S. Department of Energy’s (DOE’s ...

TORL-1-23 Demonstrates Clinically Meaningful, Durable and Confirmed Responses with a Generally Manageable Safety Profile in Patients with Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer ...